PT  - JOURNAL ARTICLE
AU  - Dunay, Gabor A.
AU  - Barroso, Madalena
AU  - Woidy, Mathias
AU  - Danecka, Marta K.
AU  - Engels, Geraldine
AU  - Hermann, Katharina
AU  - Neumann, Friederike S.
AU  - Paul, Kevin
AU  - Beime, Jan
AU  - Escherich, Gabriele
AU  - Fehse, Kristin
AU  - Grinstein, Lev
AU  - Haniel, Franziska
AU  - Haupt, Luka J.
AU  - Hecher, Laura
AU  - Kehl, Torben
AU  - Kemen, Christoph
AU  - Kemper, Markus J.
AU  - Kobbe, Robin
AU  - Kohl, Aloisa
AU  - Klokow, Thomas
AU  - Nörz, Dominik
AU  - Olfe, Jakob
AU  - Schlenker, Friderike
AU  - Schmiesing, Jessica
AU  - Schrum, Johanna
AU  - Sibbertsen, Freya
AU  - Stock, Philippe
AU  - Tiede, Stephan
AU  - Vettorazzi, Eik
AU  - Zazara, Dimitra E.
AU  - Zapf, Antonia
AU  - Lütgehetmann, Marc
AU  - Oh, Jun
AU  - Mir, Thomas S.
AU  - Muntau, Ania C.
AU  - ,
AU  - Gersting, Søren W.
TI  - Long-term antibody response to SARS-CoV-2 in children
AID  - 10.1101/2022.02.11.22270611
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.11.22270611
4099  - http://medrxiv.org/content/early/2022/02/11/2022.02.11.22270611.short
4100  - http://medrxiv.org/content/early/2022/02/11/2022.02.11.22270611.full
AB  - Almost two years into the pandemic and with vaccination of children significantly lagging behind adults, long-term pediatric humoral immune responses to SARS-CoV-2 are understudied. The C19.CHILD Hamburg (COVID-19 Child Health Investigation of Latent Disease) Study is a prospective cohort study designed to identify and follow up children and their household contacts infected in the early 2020 first wave of SARS-CoV-2. We screened 6113 children <18 years by nasopharyngeal swab-PCR in a low-incidence setting after general lockdown, from May 11 to June 30, 2020. 4657 participants underwent antibody testing. Positive tests were followed up by repeated PCR and serological testing of all household contacts over 6 months. In total, the study identified 67 seropositive children (1.44 %), the median time after infection at first presentation was 83 days post-symptom onset (PSO). Follow up of household contacts showed incomplete seroconversion in most families, with higher seroconversion rates in families with adult index cases compared to pediatric index cases (OR: 1.79, P=0.047). Most importantly, children showed sustained seroconversion up to nine months PSO, and serum antibody concentrations persistently surpassed adult levels (ratio serum IgG Spike children vs. adults 90 days PSO: 1.75, P<0.001, 180 days: 1.38, P=0.01, 270 days: 1.54, P=0.001).In a low-incidence setting, SARS-CoV-2 infection and humoral immune response present distinct patterns in children including higher antibody levels, and lower seroconversion rates in families with pediatric index cases. Children show long-term SARS-CoV-2 antibody responses. These findings are relevant to novel variants with increased disease burden in children, as well as for the planning of age-appropriate vaccination strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe C19.CHILD Hamburg Study received funding from the Senate Chancellery of the Free and Hanseatic City of Hamburg. The following foundations and organizations have provided financial support: Carlsen Verlag, Dr. Melitta Berkemann Stiftung, Foerdergemeinschaft Kinderkrebs‐Zentrum Hamburg e.V., Freunde der Kinderklinik des UK Eppendorf e.V., HSV Fussball AG, Joachim‐Herz‐Stiftung, Michael Otto Stiftung, Michael Stich Stiftung, Nutricia, Stiftung KinderHerz, EAGLES Charity Golf Club e.V., DAMP Stiftung, Kroschke Stiftung, ZEIT‐Stiftung.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethik-Kommission der Aerztekammer Hamburg Weidestr. 122 b, 22083 HamburgI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors